This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab and temsirolimus together may kill more tumor cells.

开始日期2012-06-18

申办/合作机构

National Cancer Institute

NCT00957853

/ Completed临床2期IIT

An Exploratory Study to Assess the Modulation of Biomarkers in Patients With Squamous Cell Carcinomas of the Head and Neck Randomized to Receive Preoperative Treatment With Cetuximab and/or IMC-A12, an Anti-insulin-like Growth Factor-1 Receptor Monoclonal Antibody

The goal of this clinical research study is to give cetuximab and/or IMC-A12 before surgery for squamous cell carcinoma of the head and neck, in order to learn if these study drugs may cause changes in biomarkers. Biomarkers are chemical "markers" in the blood and/or tissue that may be related to a reaction to study treatment.
The safety of the study treatments will also be studied.

开始日期2011-10-17

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

NCT01413191

/ Completed临床2期IIT

Phase II Study of IMC-A12 in Metastatic Uveal Melanoma

This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

开始日期2011-08-01

申办/合作机构

National Cancer Institute

100 项与西妥木单抗相关的临床结果

登录后查看更多信息

100 项与西妥木单抗相关的转化医学

登录后查看更多信息

100 项与西妥木单抗相关的专利（医药）

登录后查看更多信息

204

项与西妥木单抗相关的文献（医药）

2025-01-22·Journal of biomolecular structure & dynamics

Rational design of thiazolidine-4-one-gallic acid hybrid derivatives as selective partial PPARγ modulators: an in-silico approach for type 2 diabetes treatment

Article

作者: Aryan ; Malakar Kumar, Vishnu ; Jupudi, Srikanth ; Gowramma, B. ; Divakar, S. ; Babu, B. ; Chand, Jagdish

Type 2 diabetes mellitus is a bipolar metabolic disorder characterized by abnormalities in insulin production from β-cells and insulin resistance. Thiazolidinediones are potent anti-diabetic agents that act through the modulation of the peroxisome proliferator-activated receptor γ (PPARγ), a nuclear receptor. However, their full agonistic activity leads to severe side effects by stabilizing Helix12 through strong hydrogen bonding with the TYR473 residue. Partial and selective PPARγ modulators (GW0072, GQ16, VSP-51, MRL-20, MBX-213, INT131) have demonstrated superior results compared to full agonists without causing adverse effects, as reported in existing data. To address this uncertainty and advance therapeutic options, we identified and designed a novel class of compounds (A1-A23) based on a hybrid structure combining phenolic and Thiazolidine-4-one's moieties. Our rational drug design strategy incorporated structural-activity relationship principle, and validated the docking studies through calculated the root mean square deviation. Additionally, we conducted molecular docking, binding energy, molecular dynamics simulations, and post-molecular dynamics calculations to evaluate the dynamics behavior between the ligands and protein. The selected ligands demonstrated highly favorable docking scores and binding energies, comparable to the co-crystal (rosiglitazone) such as A12 (-13.9 kcal/mol and -86.2 kcal/mol), A1 (-11.1 kcal/mol and -79.5 kcal/mol), A13 (-11.3 kcal/mol and -91.4 kcal/mol), and the co-crystal itself (-9.8 kcal/mol and -76 kcal/mol), respectively. Finally, the MD revealed that, the selected ligands were equally contributed for stabilization of Helix12 and β-sheets. It was concluded, the designed ligands (A12, A1, and A13) exhibited weaker hydrogen-bond interactions with specific residue TYR473 which partially modulated the PPARγ protein.Communicated by Ramaswamy H. Sarma.

2025-01-22·Journal of biomolecular structure & dynamics

Design, synthesis, biological evaluations and in silico studies of N-substituted 2,4-thiazolidinedione derivatives as potential a-glucosidase inhibitors

Article

作者: Kumar, Rajiv ; Kumar, Rajnish ; Yadav, Ashok Kumar ; Dahiya, Lalita ; Baidya, Anurag T. K. ; Pawar, Sandip V. ; Kumar, Sunil

Diabetes mellitus is considered as one of the principal global health urgencies of the twenty first century. In the present investigation, novel N-substituted 2,4-thiazolidinedione derivatives were designed, synthesized, and characterized by spectral techniques. All the newly synthesized N-substituted 2,4-thiazolidinedione derivatives were tested for in vitro α-glucosidase inhibitory activities and compounds A-12 and A-14 were found to be the most potent which were further subjected to in-vivo disaccharide loading test. The most potent compound was also found to be non-toxic in cytotoxicity studies. Further, docking studies were carried out to investigate the binding mode and key interactions with amino acid residues of α-glucosidase. Molecular dynamic simulations studies for the compounds acarbose, A2, A12, and A14 were done with α-glucosidase protein. Further, ΔG was calculated for acarbose, A2, A12, and A14. In silico studies and absorption, distribution, metabolism, excretion (ADME) prediction studies were also executed to establish the 'druggable' pharmacokinetic profiles. Here, we have developed novel N-substituted TZD analogues with different alkyl groups as α-glucosidase inhibitors.Communicated by Ramaswamy H. Sarma.

2024-11-13·JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Design, Synthesis, and Biological Activity Studies of Myricetin Derivatives Containing a Diisopropanolamine Structure

Article

作者: An, Youshan ; Qiu, Yujiao ; Tian, Jiao ; Deng, Tianyu ; Zou, Hongqian ; Zhou, Qing ; Xue, Wei

A series of myricetin derivatives containing diisopropanolamine were designed and synthesized. The in vitro inhibitory effects of the target compounds on 9 fungal pathogens and 3 bacterial pathogens were also evaluated. A12 had the best inhibitory effect against Xanthomonas oryzae pv. oryzae (Xoo), with an EC₅₀ value of 4.9 μg/mL, which was better than zinc-thiazole (ZT: EC₅₀ = 7.3 μg/mL) and thiodiazole-copper (TC: EC₅₀ = 65.5 μg/mL); A25 had the best inhibitory effect against Phomopsis sp. (Ps), with an EC₅₀ value of 17.2 μg/mL, which was better than azoxystrobin (Az: EC₅₀ = 22.3 μg/mL). In vivo inhibition tests were performed on kiwifruit for A25 and rice leaves for A12. At 200 μg/mL, the curative activity of A12 against rice leaf blight was 40.7%, which was better than that of ZT (37.2%) and TC (32.9%), and the protective activity of A12 was 44.8%, which was better than that of ZT (39.5%) and TC (34.6%). The curative activity of A25 against kiwi soft rot disease was 70.1%, which was better than that of Az (62.8%). Preliminary elucidation of the possible mechanisms of action was carried out by experiments on fluorescence microscopy, scanning electron microscopy, formation of biofilms, density functional theory calculations, and so on.

项与西妥木单抗相关的新闻（医药）

2025-05-13

·华东医药股份有限公司

将肝脏脂肪降低最高达89%！DR10624新西兰1b/2a期临床结果发布，入选EASL 2025最新突破

近日，华东医药股份有限公司（以下简称“公司”）控股子公司浙江道尔生物科技有限公司（以下简称“道尔生物”）自主研发的全球首创（First-in-class）的靶向成纤维细胞生长因子21受体（Fibroblast growth factor 21 receptor，FGF21R）、胰高血糖素受体（Glucagon receptor，GCGR）和胰高血糖素样肽-1受体（Glucagon-like peptide-1 receptor，GLP-1R）的长效三重激动剂DR10624在新西兰治疗肥胖合并高甘油三脂血症的Ib/IIa期临床研究结果在荷兰阿姆斯特丹举办的2025年欧洲肝病研究学会年会（EASL Congress 2025）上首次发布。研究结果“DR10624, a First-In-Class, FGF21 Receptor (FGF21R)/Glucagon Receptor (GCGR)/GLP-1 Receptor (GLP-1R) Triple Agonist Rapidly and Significantly Reduced Liver Fat in Obese Subjects With Modest Hypertriglyceridemia: A 12-Week Randomized, Placebo-Controlled, Double-Blind, Multi-Center Trial”入选了大会的最新突破（Late-Breaker），展示了DR10624在肥胖合并高甘油三酯血症受试者中取得的关键研究数据。DR10624 Ib/Ⅱa期临床试验情况DR10624的Ib/Ⅱa临床试验是在新西兰开展的一项随机、双盲、安慰剂对照、多次给药剂量递增的研究。主要纳入标准为：（1）年龄为18至70岁（含界值），男性或女性；（2）筛选期BMI在30-45kg/m2范围内（含界值）；（3）筛选时空腹甘油三酯≥150 mg/dL （1.7 mmol/L），且＜500 mg/dL （5.7 mmol/L）。每个队列筛选合格的受试者按照5：1的比例接受DR10624或等体积安慰剂的皮下注射给药，给药频率为每周一次，连续给药12周。主要有效性终点为肝脏脂肪含量（Liver Fat Content，LFC）较基线变化、空腹甘油三脂（TG）较基线变化等。研究共纳入49例受试者，DR10624组41例，安慰剂组8例。所有受试者接受DR10624的各剂量组与安慰剂组间年龄、性别、体重、BMI和空腹甘油三酯水平相对均衡。DR10624在受试者中展现出优异的降低肝脏脂肪的药效。治疗12周后，DR10624的各剂量组（12.5 mg、25 mg、50 mg和75 mg剂量滴定组）的肝脏脂肪含量较基线相对降幅分别为51.9%、77.8%、79.0%和75.8%，显著高于安慰剂组的26.3%。图：与基线相比，第85天肝脏脂肪相对变化（%）在基线肝脏脂肪含量≥8%的受试者中，DR10624的各剂量组（12.5 mg、25 mg、50 mg和75 mg剂量滴定组）的LFC较基线相对降幅分别为58.3%、83%、89.2%、和87.2%，显著高于安慰剂组的27.2%。表：基线＞8%的受试者在接受12周治疗后LFC的变化（通过MRI-PDFF评估）对于肝脏脂肪含量相对降低50%这一指标（LFC相对降低50%在临床一般认为可以大概率取得脂肪肝炎的组织学缓解，即MASH resolution），DR10624的各剂量组（12.5 mg、25 mg、50 mg和75 mg剂量滴定组）中实现LFC相对降低≥50%的受试者比例分别为66.7%、88.9%、100%和85.7%。在基线肝脏脂肪含量≥8%的受试者中，DR10624所有治疗组（n=19）有94.7%在第12周实现LFC相对降低≥50%，而安慰剂组（n=6）这一比例为16.7%。DR10624在受试者中还展现出显著的降低血脂的药效。与安慰剂相比，所有DR10624治疗组的空腹甘油三酯（TG）较基线降幅均具有统计学显著性。第12周时，DR10624各剂量组（12.5 mg、25 mg、50 mg和75 mg剂量滴定组）的甘油三酯较基线相对降幅分别为31.32%、58.89%、70.16%和55.19%，而安慰剂组仅为6.94%。在50 mg和75 mg剂量滴定组中，与安慰剂相比，受试者的极低密度脂蛋白胆固醇（VLDL-C）、总胆固醇（TC）、非高密度脂蛋白胆固醇（non-HDL-C）均呈现统计学显著降低。DR10624在受试者中还展现出较好的降低胰岛素抵抗的药效。临床试验中使用胰岛素抵抗指数（HOMA-IR）来检测受试者胰岛素敏感性的变化。在第12周时，DR10624的50 mg和75 mg剂量滴定组的受试者的HOMA-IR较基线相对变化分别为-42.7%和-35.9%，而安慰剂组为+5.77%。安全性方面，DR10624在本研究中耐受性良好，未发生与研究药物相关的严重不良事件，且导致治疗终止的治疗相关不良事件发生率较低。上述Ib/IIa期临床研究数据显示，DR10624在临床每周给药一次、连续给药12周后，可实现具有临床意义的肝脏脂肪含量降低的药效，并在血脂谱改善和胰岛素敏感性提升方面展现出具有统计学意义的显著改善的疗效，使得受试者获得综合性的代谢获益。在新西兰完成的这项Ib/IIa期临床研究结果进一步验证了DR10624治疗重度高甘油三脂血症（SHTG），代谢功能障碍相关脂肪性肝病/代谢相关脂肪性肝炎（MASLD/MASH）等疾病的潜力。DR10624研发及注册情况DR10624为道尔生物自主研发的一款长效三靶点激动剂，其为靶向FGFR1c/Klothoβ（FGF21R）、GLP-1受体（GLP-1R）和GCG受体（GCGR）的候选创新蛋白药物。DR10624由N端靶向GLP-1R/GCGR的嵌合肽段与工程化改造的IgG1 Fc融合，并在Fc的C末端融合重组的FGF21突变体。DR10624注射液目前正在中国开展治疗合并肝纤维化高风险的代谢相关脂肪性肝病以及代谢合并酒精相关脂肪变性肝病II期临床研究，并于2025年4月完成首例受试者入组。与此同时，此前在中国已启动的另一项DR10624治疗重度高甘油三酯血症的II期临床研究已完成全部患者入组，预计2025年第三季度获得揭盲后的顶线结果。此外，DR10624用于2 型糖尿病和体重适应症的中国临床试验申请也先后获批。声明1、本新闻旨在分享公司（或合作伙伴）研发工作的前沿进展资讯，非广告用途，相关信息并非针对患者，仅供医疗卫生专业人士参考使用；2、本新闻稿中内容不涉及对任何药品和/或适应症作推荐；3、本新闻稿中涉及的信息仅供参考，具体信息以公司在深圳证券交易所发布的文件为准。公司新闻稿和公告不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导；4、本新闻稿中涉及的产品包装仅供参考，具体请以实际为准；5、截至本文发布，DR10624注射液尚未被国家药品监督管理局批准上市；6、本新闻稿中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，均属于前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述是基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些是超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本网站所载前瞻性表述的任何义务;及 (b) 若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。

临床结果临床2期临床1期

2025-04-15

·华东医药股份有限公司

英文版 | 创新研发进展不断！华东医药将携十大创新药项目亮相国际大会

Guided by its corporate philosophy of Scientific Research-based and Patient-centered', Huadong Medicine has dedicated itself to advancing treatments in cancer, autoimmune disorders, and chronic metabolic diseases." By continuously increasing R&D investment and actively promoting the progress of clinical trials, we have achieved several significant milestones. In particular, ten of our proprietary research results are scheduled for presentation at major global conferences in the first half of 2025, including the annual meetings of American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Diabetes Association (ADA) and European Association for the Study of the Liver (EASL). These presentations will highlight our pioneering contributions to global healthcare innovation.012025AACRThe 2025 Annual Meeting of the American Association for Cancer Research (AACR) will be held from 25 to 30 April in Chicago, USA. As the world's oldest and largest cancer research conference, the AACR will bring together leading scientists, pharmaceutical innovators, and research institutions to highlight high-impact cancer studies and cutting-edge therapeutic advances, showcasing the latest breakthroughs in oncology. At this premier event, Huadong Medicine will make a groundbreaking debut with five novel proprietary therapies selected for poster presentations, including HDM2022: A first-in-class GSPT1 molecular glue degrader with potent anti-tumour activity；HDM2006: The first oral HPK1-targeting PROTAC (proteolysis-targeting chimera) for hematopoietic progenitor kinase inhibition；Three next-generation ADCs, HDM2012: Targeting MUC17 for gastrointestinal cancers, HDM2017: Targeting CDH17 for metastatic solid tumours, HDM2020: An FGFR2b-specific ADC designed for precision therapy in resistant malignancies. These innovations underscore Huadong Medicine's achievements in pioneering transformative oncology solutions.2025H1: Posters at AACRApril 27th2:00PM-5:00PMPoster Section:10 Board Number:13Preclinical development of HDM2020, a novel ADC targeting FGFR2b, in gastric cancer (GC) and squamous non-small cell lung cancer (sq-NSCLC) xenograft modelsAbstract No. 245 Poster Section:15 Board Number:8Translational studies of HDM2012, a novel topoisomerase inhibitor ADC targeting MUC17, in patient derived GC, CRC, PDAC tumor models Abstract No. 316 Poster Section:15 Board Number:9Discovery of HDM2017, a CDH17-targeting ADC for colorectal cancersAbstract No. 317 Poster Section:18 Board Number:383Discovery of potent, selective, and orally bioavailable GSPT1 molecular glue degraders (MGDs) for the treatment of MYC-driven tumors Abstract No. 2161April 29th2:00PM-5:00PM Poster Section:21 Board Number:10HDM2006, A Novel and Potent HPK1 PROTAC, Enhances Immune Cell Activation and Induces Robust Tumor Growth InhibitionAbstract No. 5632022025ASCOThe American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from 30 May to 3 June 2025, is the world's leading professional scientific organization in oncology and is one of the largest and most prestigious global oncology conferences. It serves as a premier platform for the presentation of cutting-edge research and clinical trial data in cancer care.Huadong Medicine will be showcasing its proprietary anti-tumour drug HDM2025 through a poster presentation at this prestigious event. This innovative therapeutic agent demonstrates potent and selective pan-KRAS targeting capabilities, marking a significant advancement in the development of oncology therapeutics.2025H1: Poster at ASCOJune 2nd1:30PM-4:30PMPoster Section:15 Board Number:428Discovery of Potent Degraders of pan-KRAS Based on a Novel KRAS Binder032025ADAThe 85th American Diabetes Association (ADA) Scientific Sessions, a major international academic event in the field of diabetes, will take place in Chicago, USA, from June 20-23, 2025. This esteemed congregation will bring together clinicians, researchers, educators and industry leaders to advance discussions on diabetes-related basic research, clinical practice, prevention strategies and technological innovation. At this landmark conference, Huadong Medicine will present groundbreaking achievements: The company's self-developed GLP-1/GIP dual-target long-acting agonist, HDM1005 Injection, has been selected for an Oral Presentation, emphasizing its innovative therapeutic potential. The poster presentations will feature the company's proprietary research on HDM1002-102, an oral small-molecule GLP-1 agonist, along with Phase III clinical trial results of Semaglutide Injection, highlighting Huadong Medicine' leadership in advancing diabetes care.2025H1: Oral Presentation&Posters at ADAJune 20th5:45PM-6:00PMAbstract Number：142-ORSafety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation StudyJune 22nd12:30PM-1:30PMAbstract Number：737-PHDM1002 in Chinese Adults with Overweight or Obesity-A Randomized, Placebo-Controlled, Four-Week, Phase 1b StudyAbstract Number：839-PEfficacy and Safety of HDG1901 vs Ozempic® in Patients with Type 2 Diabetes (T2D): A Randomized, Open-label, Bioequivalence Phase 3 Trial042025EASLConcurrently, Huadong Medicine' subsidiary Doer Biologics will present groundbreaking clinical research data at the European Association for the Study of the Liver (EASL) Annual Congress 2025, a leading international event in hepatology, taking place in Amsterdam, the Netherlands, from 7 to 10 May. The company will be showing data from its New Zealand-based multi-ascending dose (MAD) study of DR10624-101, an Fc fusion protein drug developed using its proprietary MultipleBody® platform technology, in a poster presentation. DR10624 is the "first-in-class" and the world's first tri-target agonist activating three critical receptors: the glucagon-like peptide-1 receptor (GLP-1R), glucagon receptor (GCGR), and FGFR1c/Klothoβ (FGF21R). This positions it as a pioneering advancement in the field of metabolic and liver disease therapeutics. 2025H1: Posters at EASLMay 7th8:30AM-4:00PMAbstract identifier: LBP-003/FRI-365Late breakerDR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hypertriglyceridemia: a 12-week randomized, placebo-controlled, double-blind, multi-center trialMay 9th8:30AM-5:00PMDR10624, a novel FGF21R, GCGR, and GLP-1R tri-agonist, demonstrated extraordinary efficacy in B6-Alms1-del mice, a spontaneous MASH model of mice with obesity, hyperglycemia, and dyslipidemia phenotypeHuadong Medicine's participation in a series of leading international academic conferences to highlight its proprietary innovations underscores the growing global recognition of its pioneering R&D capabilities. In the future, Huadong Medicine will continue to commit to its core philosophy of 'Scientific Research-based and Patient-centered' by pursuing proprietary research and strategic collaborations to expand innovative product pipeline,aim to become a powerful international pharmaceutical enterprise driven by scientific research innovation.Statements1.This news article is intended to share frontline updates on the R&D progress of the company (or its partners) and is not for advertising purposes. The information provided is not directed at patients and is for reference by healthcare professionals only.2.This press release does not endorse or recommend any specific pharmaceutical product and/or indication.3.The information contained herein is for reference only and shall be subject to the documents officially released by the company on the Shenzhen Stock Exchange. Neither this press release nor company announcements shall replace professional medical guidance or be construed as diagnostic or treatment advice. For specific disease-related information, please consult physicians or other qualified healthcare professionals.4.As of the date of this release, HDM1002, HDM1005, HDM2006, HDM2012, HDM2017, HDM2020, HDM2022, HDM2025, DR10624, and HDG1901 (the company’s semaglutide injection) have not been approved for marketing by the National Medical Products Administration (NMPA).5.This press release may contain forward-looking statements. Such statements inherently involve risks and uncertainties. Terms such as “anticipate,” “believe,” “predict,” “expect,” “intend,” and similar expressions, when related to the Company, constitute forward-looking statements. The Company is under no obligation to continuously update these predictive statements.These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts, and understandings of the Company’s management regarding future events at the time of publication. They are not guarantees of future performance and are subject to risks, uncertainties, and other factors beyond the Company’s control. Actual results may differ materially from those expressed or implied due to changes in the Company’s business, competitive landscape, and political, economic, legal, and social conditions.The Company, its directors, employees, and agents shall not be liable for (a) any obligation to correct or update forward-looking statements contained herein; or (b) any consequences arising from the failure of such forward-looking statements to materialize or their inaccuracy.v

抗体药物偶联物ASCO会议AACR会议

2025-02-17

·石药集团

丁苯酞：预防卒中后认知障碍新证据发表

近日，由天津医科大学总医院王景华、宁宪嘉教授团队完成的研究成果《Efficacy of butylphthalide in preventing cognitive decline in ischaemic stroke survivors: a 12-month prospective following-up study》在《Stroke & Vascular Neurology》杂志上发表。研究结论显示，丁苯酞能有效预防缺血性卒中患者12个月后的认知能力下降，相较于对照组，丁苯酞用药12个月后发生认知障碍的风险降低了38.8%。表明丁苯酞可以被纳入标准卒中后护理方案，以改善患者预后并减轻医疗负担。本研究是一项为期12个月的前瞻性随访研究。纳入居住在天津年龄≥18岁，发病1-6个月内（非急性期）的非心源性缺血性卒中患者，分为丁苯酞软胶囊治疗组和对照组。评估用药12个月后丁苯酞对预防缺血性卒中患者认知功能下降的有效性。研究时间为2021.4-2023.3，共有605例患者被纳入本研究的分析（丁苯酞组309例，对照组296例）。主要疗效结果显示 1）丁苯酞能减轻缺血性卒中患者MMSE评分的下降程度（D值及D值百分比）； 2）丁苯酞能减轻缺血性卒中患者定向力和语言能力的下降程度（D值及D值百分比）； 3）多因素分析表明，丁苯酞治疗与MMSE评分的改变、定向力和语言能力的改变均呈独立负相关；年龄≥60岁和较低的教育水平被认为是认知能力下降的危险因素。如下图：次要疗效结果显示 12个月时，丁苯酞组有51名患者（16.5%）出现认知功能下降，对照组有71名患者（24.0%）出现认知功能下降，两组差异有统计学意义（P=0.022）；多因素分析表明，丁苯酞治疗与较低的认知功能下降风险相关（OR=0.612; P= 0.020），与对照组比较，丁苯酞组一年后发生认知障碍的风险降低了38.8%。如下图：本研究表明丁苯酞用药12个月可以有效减少缺血性卒中患者的认知评分下降和认知功能下降的发生率，降低卒中患者的长期医疗保健需求和相关成本。随着越来越多研究结果的公布，丁苯酞软胶囊在认知障碍方面的疗效将得到进一步验证。【声明】1、本新闻旨在分享研究进展信息，非广告用途； 2、本资料仅供医药专业人士参考，非产品推荐依据，也不应被视为诊疗建议。

临床结果

100 项与西妥木单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09328	西妥木单抗	-	DB12250

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺泡软组织肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
肺泡软组织肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18
尤文肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
尤文肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18
神经胶质肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
神经胶质肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18
血管肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
血管肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18
脂肪肉瘤	临床2期	美国	National Cancer Institute	2012-06-18
脂肪肉瘤	临床2期	加拿大	National Cancer Institute	2012-06-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01413191 (Pubmed \| Melanoma Res) 人工标引	临床2期	葡萄膜黑色素瘤	18	imc-a12	築醖糧願艱遞餘壓襯構(遞糧窪衊觸範壓願窪鹹) = 觸夢蓋積簾願遞艱艱網廠製顧膚製艱遞蓋廠襯 (夢構鏇餘鬱繭鏇願衊觸 ) 更多	不佳	2020-12-01
NCT01026623 (Pubmed \| Clin Genitourin Cancer) 人工标引	临床1期	转移性去势抵抗性前列腺癌	16	cixutumumab+Temsirolimus (cohort 1)	窪齋範網蓋鹹憲衊築鬱(觸夢範顧鏇遞齋艱窪鬱) = The most common adverse events included hyperglycemia (100%; 31% grade 3), oral mucositis (63%; 19% grade 3), and diarrhea (44%; 0 grade 3). Low-grade pneumonitis occurred in 7 of 11 patients (44%; 0 grade 3). 願遞鬱遞積鏇蓋衊襯遞 (構鹹鹹糧鏇壓遞鹹積範 ) 更多	不佳	2020-06-01
				cixutumumab+Temsirolimus (cohort -1)
NCT00957853 (CTgov)	临床2期	头颈部鳞状细胞癌	16	Cetuximab (Cetuximab)	淵餘鑰顧鑰簾齋網膚獵 = 築繭艱網築蓋鹽衊積鏇積範構壓繭廠鹹淵範餘 (襯壓築醖淵鹹糧窪鬱構, 餘築築觸選製壓窪窪醖 ~ 衊鹽鹹鹹醖獵積製鏇夢) 更多	-	2020-03-19
				IMC-A12 (IMC-A12)	淵餘鑰顧鑰簾齋網膚獵 = 願餘觸衊選製膚構簾鬱積範構壓繭廠鹹淵範餘 (襯壓築醖淵鹹糧窪鬱構, 願餘艱淵醖網淵範製憲 ~ 壓艱網廠齋鬱壓壓蓋製) 更多
NCT01120236 (SWOG S0925, ASCO_GU2020)	临床2期	去势抵抗性前列腺癌	210	Androgen deprivation + cixutumumab	窪夢鹹廠鹽衊憲餘鹽淵(艱鹹襯餘繭製繭餘糧壓): HR = 1.01 (95% CI, 0.7 ~ 1.45), P-Value = 0.97 更多	不佳	2020-02-19
				Androgen deprivation
NCT01263782 (CTgov)	临床2期	晚期非小细胞肺癌	64	Carboplatin+Pemetrexed (Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe)	網遞製夢齋餘積夢顧艱(艱繭醖鏇壓遞遞糧觸壓) = 鏇製淵顧廠鑰獵憲窪選鏇糧艱獵簾築網餘餘網 (醖簾窪選願願鏇膚觸願, 餘遞繭膚構廠齋醖顧齋 ~ 網夢廠獵餘簾遞鬱網壓) 更多	-	2019-05-08
				Carboplatin+Pemetrexed+Bevacizumab (Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance)	網遞製夢齋餘積夢顧艱(艱繭醖鏇壓遞遞糧觸壓) = 選膚選範襯選鏇糧構膚鏇糧艱獵簾築網餘餘網 (醖簾窪選願願鏇膚觸願, 憲鬱簾鑰繭夢鬱糧鹹構 ~ 築廠鹽築遞選獵壓構鏇) 更多
NCT01007032 (CTgov)	临床1期	晚期恶性实体瘤	21	Cixutumumab (Cixutumumab Cohort 1)	艱鏇遞網夢鹹簾糧顧願 = 艱鬱網鏇鏇艱獵夢淵構鏇簾鹽蓋鏇顧窪窪選艱 (夢鏇獵顧遞鑰網餘選鑰, 艱構鹹簾廠築製鬱憲簾 ~ 獵餘範夢鹽築壓網鑰餘) 更多	-	2019-02-27
				Cixutumumab (Cixutumumab Cohort 2)	艱鏇遞網夢鹹簾糧顧願 = 蓋觸淵夢鹹襯選廠遞憲鏇簾鹽蓋鏇顧窪窪選艱 (夢鏇獵顧遞鑰網餘選鑰, 網積鏇觸壓夢餘鹹構鑰 ~ 餘顧鏇餘鏇齋遞夢餘簾) 更多
NCT00785538 (CTgov)	临床1期	晚期恶性实体瘤	24	IMC-A12 (3 mg/kg)	築膚膚壓鏇範餘淵艱齋 = 廠壓壓簾夢鏇衊選繭範壓糧壓顧願窪範壓簾憲 (憲糧遞鹽構範窪網壓簾, 鏇鏇網襯憲顧膚衊鏇鹽 ~ 顧憲餘鏇窪憲觸製淵鏇) 更多	-	2018-10-22
				IMC-A12 (6 mg/kg)	築膚膚壓鏇範餘淵艱齋 = 齋衊積艱製鹽築顧衊鑰壓糧壓顧願窪範壓簾憲 (憲糧遞鹽構範窪網壓簾, 醖糧醖製繭艱鑰淵繭餘 ~ 積鏇製顧襯範餘淵築鹹) 更多
NCT00520481 (CTgov)	临床2期	转移性前列腺癌 \| 前列腺腺癌	41	Cixutumumab (Cixutumumab 10 mg/kg)	艱廠餘憲夢鏇獵醖鏇繭(觸蓋膚範醖壓築範網衊) = 繭鬱憲願築獵製願鏇鏇鑰選觸鑰遞醖壓餘觸鹹 (顧鹽餘鹹範構齋鬱築糧, 窪壓餘鹹網積壓獵鬱顧 ~ 遞糧遞遞繭網淵觸鹽範) 更多	-	2018-07-19
				Cixutumumab (Cixutumumab 20 mg/kg)	艱廠餘憲夢鏇獵醖鏇繭(觸蓋膚範醖壓築範網衊) = 衊繭夢窪網壓廠襯憲遞鑰選觸鑰遞醖壓餘觸鹹 (顧鹽餘鹹範構齋鬱築糧, 鹹構鏇淵顧顧鹹餘憲窪 ~ 窪鬱壓衊壓構衊齋衊簾) 更多
NCT00668148 (CTgov)	临床2期	外周性原始神经外胚层肿瘤 \| 平滑肌肉瘤 \| 横纹肌肉瘤 ... 更多	113	IMC-A12 (cixutumumab) (Ewing's Sarcoma/PNET)	範糧艱鹹選構衊構鏇糧 = 膚遞鹹願夢壓壓襯鬱膚鏇窪鹹淵構願夢齋窪鹽 (憲糧鏇顧繭醖繭鏇醖夢, 網構醖鏇夢蓋積鏇壓遞 ~ 壓夢襯鬱選鏇繭艱壓鬱) 更多	-	2018-07-17
				IMC-A12 (cixutumumab) (Rhabdomyosarcoma)	範糧艱鹹選構衊構鏇糧 = 鹽餘獵鹹鏇範襯艱艱壓鏇窪鹹淵構願夢齋窪鹽 (憲糧鏇顧繭醖繭鏇醖夢, 鑰鹹獵衊積願遞繭網鏇 ~ 鏇顧鑰製獵膚餘鹹壓蓋) 更多
NCT00617734 (Pubmed) 人工标引	临床2期	复发性头颈部鳞状细胞癌	91	Cixutumumab+cetuximab	鬱願壓積淵壓簾艱遞鑰(窪壓遞鏇鬱齋醖壓憲憲) = 壓鬱蓋醖顧淵繭鏇膚蓋衊蓋繭夢構積築遞範繭 (糧壓夢襯窪鬱廠淵蓋製 ) 更多	不佳	2018-07-01
				Cixutumumab	鬱願壓積淵壓簾艱遞鑰(窪壓遞鏇鬱齋醖壓憲憲) = 艱鏇壓選構廠襯衊鬱簾衊蓋繭夢構積築遞範繭 (糧壓夢襯窪鬱廠淵蓋製 ) 更多